Literature DB >> 31695005

[Spontaneous remission of acquired factor XIII inhibitor concurrent to development of IgA-λ type multiple myeloma].

Shikiko Ueno1, Junko Nozaki2, Shinichi Kusano1, Yawara Kawano1, Yoshitaka Kikukawa1, Yutaka Okuno1, Hiroyuki Hata3, Masao Matsuoka1, Mitsuhiro Uchiba4.   

Abstract

Coagulation factor XIII is a fibrin-stabilizing factor that leads to the crosslinking of fibrin when activated by thrombin. Acquired factor XIII inhibitor is caused when antibodies are generated against factor XIII, reducing its activity. Here we report a case of acquired factor XIII inhibitor. Although prednisolone was administered, factor XIII activity was not recovered. Interestingly, the activity normalized following the onset of multiple myeloma. The presence of inhibitors was evaluated in the patient's plasma by absorption tests and enzyme-linked immunosorbent assay. Immunoglobulin G inhibitors of factor XIII were present at admission, but later decreased with the onset of the IgA-λ-type myeloma. Thus, it is possible that the level of factor XIII inhibitors and polyclonal immunoglobulins could have been suppressed by the progression of myeloma, resulting in the normalization of factor XIII activity.

Entities:  

Keywords:  Acquired factor XIII inhibitor; Multiple myeloma

Mesh:

Substances:

Year:  2019        PMID: 31695005     DOI: 10.11406/rinketsu.60.1443

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

Review 1.  Measuring Factor XIII Inhibitors in Patients with Factor XIII Deficiency: A Case Report and Systematic Review of Current Practices in Japan.

Authors:  Shiho Amano; Kohei Oka; Yutaka Sato; Chiaki Sano; Ryuichi Ohta
Journal:  J Clin Med       Date:  2022-03-18       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.